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Abstract
Nanoparticles are vastly studied drug delivery systems aiming at altering or improving the 
pharmacokinetics and pharmacodynamics of both low and high molecular weight drugs. 
Among the different materials used in the preparation of nanoparticulate drug delivery 
systems, polysaccharides offer several benefits, such as versatility, biodegradability and 
biocompatibility. Nanoparticles based on polysaccharides are thus promising drug delivery 
systems. In the formulation of new drug delivery systems, the understanding of the 
mechanisms and parameters affecting their properties is essential.  
The considerations summarized above laid the grounds for this thesis with the overall aim of 
investigating parameters that could affect the preparation and physicochemical 
characteristics of nanoparticles based on the polysaccharides chitosan and pectin for 
potential applications in drug delivery. The main results obtained are reported in four papers 
that cover the development of a method for the estimation of the nanoparticle compactness, 
the preparation and characterization of nanoparticles based on chitosan or pectin, and the 
colloidal stability of the nanoparticles. Moreover, initial studies on the potential 
mucoadhesive properties of selected chitosan and pectin based nanoparticles are reported in 
this thesis summary. 
The results presented demonstrate that both chitosan and pectin nanoparticles could be 
prepared by ionotropic gelation in the presence of sodium chloride, while chitosan 
microparticles and a macroscopic pectin network were formed in the absence of sodium 
chloride. The nanoparticle characteristics could easily be adjusted by changing the solvent 
salinity, the type and concentration of polysaccharide, and the crosslinker to polysaccharide 
ratio applied in the particle preparation. The main differences between the chitosan and the 
pectin nanoparticles were their positive and negative charge, respectively, and that the 
chitosan nanoparticles were generally smaller and more compact than the pectin 
nanoparticles. Both the chitosan and the pectin nanoparticles studied were mainly found to 
be colloidally stable after one week of storage. The chitosan nanoparticles interacted more 
strongly with mucin than the pectin nanoparticles in vitro, indicating a stronger ability to 
adhere to the body’s protective mucus gel layer. 
The findings in this thesis offer a decent platform for further studies on the applicability of 
polysaccharide based nanoparticles for drug delivery applications. 
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1 Background
The term “drug delivery” refers to approaches or systems for administering a 
pharmaceutical active ingredient to achieve a therapeutic effect in humans or animals. These 
approaches or systems aim to improve treatment efficacy, safety and/or patient compliance 
and may involve the use of different medical devices, administration routes and drug 
formulations. Firstly, different medical devices can aid access to secluded parts of the 
human body, exemplified by the use of inhalators for improved drug delivery to the inner 
parts of the lungs. Secondly, different administration routes can be used for direct drug 
delivery to the site of action for local treatment, or for systemic drug delivery. The buccal 
administration route may for instance be used both for direct topical delivery of miconazole 
in the treatment of oral fungal infections [1, 2], and for systemic uptake of insulin in the 
treatment of Type I and Type II diabetes [3, 4]. Finally, different drug formulations or drug 
delivery systems (DDSs) may be used to modify the release profile, absorption, distribution, 
degradation or elimination of the active ingredient in the body to improve drug treatment. 
Conventional DDSs are associated with a number of limitations when it comes to 
facilitating drug absorption, accessing the target site and timing the therapeutic effect [5, 6]. 
As further addressed below, nanoparticles offer new possibilities in the search for the 
“ideal” DDS; a system that is able to deliver the correct amount of drug to the desired site of 
action, at the correct rate and time, without any undesirable side-effects.  
Polysaccharides are commonly used materials in the design of DDSs because they are 
generally regarded as biocompatible and biodegradable, and can possess other desired 
properties, such as the ability to adhere to the body’s mucosal linings. Polysaccharide based 
nanoparticles may hold the positive features of both nanoparticles and polysaccharides, and 
are suitable for both parenteral and mucosal administration of drugs [7-11].  
The work presented in this thesis is an initiating study on nanoparticles based on the 
mucoadhesive polysaccharides chitosan and pectin for potential use as DDSs for mucosal 
administration. The work has particularly aimed at investigating the challenges connected to 
preparation of ionically crosslinked nanoparticles at relatively high polysaccharide 
concentrations and the estimation of the nanoparticle compactness. 
Introduction 
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2 Introduction
2.1 Nanoparticlesindrugdelivery
2.1.1 Nanoparticlesasdrugdeliverysystems
Nanoparticles can be defined as particles of various shapes having a size in the range 1 to 
1000 nm. They can be comprised of both inorganic and organic constituents. This work, 
however, will focus on nanoparticles build up by organic materials, such as lipids, proteins, 
synthetic polymers and polysaccharides, with emphasis on the latter. Nanoparticles can act 
as drug delivery systems, having the drug entrapped in the interior structure, adsorbed to the 
surface, or covalently attached to the precursor materials [6, 11]. Since nanoparticles fall 
into the size range of macromolecular structures and proteins found inside living cells, they 
may take advantage of existing cellular machinery to deliver drugs [12].  
One fundamental property of nanoparticles renders them different from their bulk materials, 
and that is the large surface-to-volume ratio [13]. This property may be exploited in 
formulation of hydrophobic drugs, for which an increase in surface area will increase the 
drug dissolution rate and enhance absorption [14]. The nanoparticles can also be taken up 
directly by cells in the mucosa through endocytosis [15, 16]. The composition of the 
nanoparticles may further enhance drug permeation and absorption, for instance by 
transiently opening tight junctions to facilitate paracellular drug or particle absorption [17]. 
In a study of solid-lipid-nanoparticles loaded with the biopharmaceutical classification 
system Class II drug cyclosporine A, a significant improvement in systemic drug levels was 
found if compared to drug nanocrystals after oral administration in pigs [18, 19]. This 
illustrates both the effect of the nanoparticle size and the composition on the bioavailability 
of the hydrophobic drug.  
Certain pharmaceuticals such as proteins and peptides are easily degraded when 
administered orally and are often rapidly eliminated after intravenous injection [20, 21]. The 
incorporation of such pharmaceuticals in nanoparticles has therefore been exploited to 
protect them against premature physiological degradation and elimination [8, 16]. Cui et al. 
found for instance that PLGA (poly(D,L-lactide-co-glycolide)) nanoparticles containing 
hypromellose phthalate can protect insulin from the gastrointestinal environment, illustrated 
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by significantly reduced serum glucose levels after oral administration in rats, if compared 
with insulin solution [22]. 
Several physicochemical parameters may influence the biodistribution of nanoparticles after 
administration [23]. The penetration of nanoparticles through the protective gel layer 
covering the body’s mucosal linings is for instance dependent on the size and surface 
characteristics [24, 25]. Studies have shown that nanoparticles smaller than approximately 
200 nm can effectively diffuse through this gel layer, and that polystyrene nanoparticles 
coated with the uncharged hydrophilic polymer polyethylene glycol (PEG) penetrate more 
easily than uncoated polystyrene nanoparticles [26-28] . 
Similar effects of size and surface characteristics have been found for the in vivo 
distribution and circulation of nanoparticles after intravenous injection. Coating the 
nanoparticles with PEG can for instance reduce the degree of opsonisation and clearance of 
the nanoparticles through the reticuloendothelial system in the liver, spleen and bone 
marrow, leading to longer circulation times and possibly enhanced deposition at the desired 
site [29, 30]. Rigid, spherical particles with a size of 100-200 nm are usually considered 
having the highest potential for prolonged circulation, as they  are sufficiently large to avoid 
uptake in the liver and sufficiently small to avoid filtration in the spleen [29]. However, 
deformable soft nanoparticles of larger sizes may exhibit similar potentials [29]. 
Nanoparticles in the size range 100-200 nm are also attractive for passive targeting to 
tumors through the enhanced permeability and retention effect [30].   
The surface of the nanoparticles can also be modified with ligands for targeted delivery, for 
example by incorporation of folate to target human cancer cells with an over-expression of 
folate receptors [12, 29]. There is also increasing  interest in stimuli-responsive 
nanoparticles that can target or release the drug at a desired site or time upon exposure to 
various stimuli, such as physiological changes in pH or an externally applied magnetic field 
[13, 31, 32]. 
As shortly commented above, the fate of the nanoparticles in the human body is highly 
dependent on the physicochemical properties size, surface characteristics and 
deformability/compactness. These properties may also affect other important factors, such 
as the drug release profile [33-35] and the toxicity profile of the delivery system. It has for 
instance been reported that cationic nanoparticles can cause hemolysis and blood clotting, 
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while neutral and anionic nanoparticles are rather nontoxic [36]. The toxicity profile of the 
DDS is also linked to the properties of the precursor materials themselves [36]. The 
precursor materials and their possible degradation products should hence be biocompatible, 
and preferably biodegradable or able to be eliminated from the body to avoid accumulation 
and possible long-term toxicity. The size, charge and compactness of the nanoparticles also 
affect the colloidal stability in suspension [37-39], which can be of importance in the 
development of a final drug product suitable for commercialization.  
2.1.2 Nanoparticlesandmucosaladministration
Much effort has been put into developing nanoparticles for the mucosal administration of 
drugs (e.g., by the oral, buccal and nasal administration routes), aiming for either enhanced 
systemic uptake or improved effect locally. These mucosal routes can be advantageous as 
they are less invasive than parenteral routes and do not require the production of sterile 
DDSs. However, these routes have a natural degrading and protective function which 
complicates the drug formulation development. 
2.1.2.1 The mucus barrier 
The mucosal epithelial linings in the body consist of tightly bound cells and are covered 
with a mucus gel layer for protection against the external environment. This protective layer 
is mainly composed of crosslinked and entangled mucin fibers forming a viscoelastic 
hydrogel consisting of typically 90-98% water [24, 25]. The pore size of the mucus network 
depends on the mucosal site and disease state, and can be in the range 50-1800 nm [40]. The 
mucus gel also contains other proteins, enzymes, antibodies, carbohydrates, lipids, salts, 
bacteria, cells and cellular debris, and is continuously cleared and replaced by the body [24]. 
The protective character of the mucus layer makes a natural barrier for drug penetration to 
the underlying cells for local therapeutic effects or systemic absorption. Therefore, DDSs 
that are able to either penetrate into or adhere to the mucus are widely studied for 
prolonging the retention time of the drug in close proximity to the site of action or 
absorption. Prolonged retention time may lead to a sustained drug delivery and reduced 
dosage frequency, and possibly improve patient compliance. A schematic representation of 
possible interactions between DDSs and the mucus layer is given in Figure 2.1. The figure 
illustrates the possibilities of interaction by polymer entanglements between polymer chains 
in the DDS and the mucin fibers, and the penetration of nanoparticles through the pores of 
the mucus gel network. More specific interactions between the DDS and the mucin fibers 
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may also contribute to the mucoadhesion, such as hydrophobic associations, electrostatic 
interactions and covalent bonds [24, 25].  
The penetration of nanoparticles through the protective mucus layer is dependent on the 
particle size: it must be sufficiently small so that the particles can diffuse through the pores 
in the mucus mesh. Due to specific interactions with the mucus, conventional mucoadhesive 
nanoparticles generally penetrate the upper mucus layer only and do not easily reach the 
underlying epithelia [24, 25, 27, 28, 41]. A more novel approach to improve drug delivery at 
mucosal sites is to overcome the mucosal barrier by preparing mucus-inert nanoparticles 
that mimic the surface properties of viruses capable of diffusing in mucus as fast as in water 
[24, 25]. Hence, coating nanoparticles with uncharged and hydrophilic PEG of low-
molecular weight has been found to increase the extent of mucus penetration with respect to 
uncoated hydrophobic nanoparticles [26, 27].  
 
Figure 2.1 – Schematic representation of the interaction of DDSs with the mucus layer. Upper left: 
mucoadhesive nanoparticles penetrating into the luminal mucus layer and sticking to the mucin fibers 
through hydrophobic associations or electrostatic interactions. Lower left: mucus-inert nanoparticles 
penetrating to the more stagnant mucus layer. Upper right: a mucoadhesive tablet sticking to the surface 
of the mucus layer. [25] 
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To summarize, the potential advantages of nanoparticulate systems for improved delivery of 
drugs include 1) sustained maintenance of drug concentrations within the therapeutic 
window, 2) facilitation of administration of easily degradable agents, such as peptides and 
proteins, 3) decreased dosage frequency and possibly less invasive dosing, promoting 
patient compliance, 4) reduction of harmful side effects due to targeted delivery to a 
particular cell type or tissue, and 5) reduced manufacturing costs due to a reduction in the 
amount of drug needed or reduced microbiological requirements of the DDS [42]. These 
advantages must of course be balanced against 1) accumulation and toxicity of the materials 
or their degradation products, 2) unwanted rapid or burst release of the drug from the DDS, 
3) increased discomfort of the DDS, and 4) expense of the DDS due to sophisticated 
manufacturing procedures or expensive materials [42]. 
2.2 Polysaccharidebasednanoparticlesformucosaladministration
2.2.1 Polysaccharides
Polysaccharides are linear or branched long-chained molecules composed of repeating sugar 
units adjoined by glycosidic bonds. They are highly abundant in nature and generally have 
low processing costs [11]. They can be of algal, plant, microbial or animal origin, and are 
widely used in formulation of both conventional and novel DDSs. Common examples of 
polysaccharides used in drug delivery are alginate, chitosan, hyaluronic acid, pectin and 
cellulose derivatives, such as hydroxyethyl cellulose and carboxymethylcellulose. 
Polysaccharides come in a wide range of molecular weights and chemical compositions, and 
can be divided into polyelectrolytes or non-polyelectrolytes, depending on the presence of 
ionizable functional groups. Due to a large number of reactive groups, most typically 
hydroxyl groups, they can easily be modified chemically and biochemically. This feature 
can be exploited in drug delivery, e.g., by conjugating drugs to the polysaccharides for 
sustained release, or by attaching ligands for targeting to a desired site.  
Polysaccharides are hydrophilic in nature and may form macroscopic hydrogels at 
sufficiently high concentrations (above the overlap concentration) in the presence of cross-
linkers or other substances inducing polymer-polymer interactions [7, 43]. The 
conformation of the polysaccharides in solution and the gelling properties are dependent on 
the balance between solvent-solute, solute-solute and solvent-solvent interactions, and is 
thus usually dependent on the solvent properties and the presence of co-solutes. 
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Polysaccharides are generally regarded as biocompatible, biodegradable and non-
immunogenic, and hence safe materials for drug delivery. However, some conflicting results 
have been reported for the polysaccharide chitosan [44]. Another drawback of 
polysaccharides for drug delivery purposes is the potentially significant batch-to-batch 
variation due to their natural origin. 
The degradation of polysaccharides in vivo is generally due to hydrolytic and enzymatic 
cleavage of the glycosidic bonds, and is highly dependent on the site of administration. 
Polysaccharides like pectin and chitosan are for instance enzymatically degraded by the 
bacteria in the colon, but to a small extent in the small intestine [17, 45, 46]. Hence, DDSs 
based on chitosan and pectin for possible drug targeting to the colon have been investigated 
[46-49]. Furthermore, polysaccharides, such as hyaluronic acid can be used for active 
targeting to cells expressing carbohydrate-binding cell-surface receptors [10, 50]. Several 
polysaccharides, like alginate and chitosan also possess mucoadhesive properties that can be 
exploited in mucosal delivery of drugs [51]. 
2.2.2 Preparationofpolysaccharidebasednanoparticles
Polysaccharide based nanoparticles can be prepared by different preparation methods, which 
can be divided into four categories: (1) covalent crosslinking, (2) ionic crosslinking, (3) 
polyelectrolyte complexation, and (4) self-assembly [11]. The different methods are briefly 
introduced below. The drug can either be physically entrapped during nanoparticle 
formation, covalently attached to the precursor materials, or absorbed or adsorbed to the 
nanoparticles post-preparation. Nanoparticles are often unstable in suspension, and as a final 
step, the nanoparticles are therefore often freeze-dried (in the presence of a suitable 
cryoprotectant) to extend their shelf-life [52]. The nanoparticles can be resuspended in a 
proper medium before administration. Another approach for extending the shelf-life is 
spray-drying into a microparticulate powder [52], which can be suitable for direct 
administration by inhalation or compression into tablets.  
Covalent crosslinking 
Nanoparticle preparation by covalent crosslinking involves the introduction of covalent 
bonds between the polysaccharide chains. This enables preparation of relatively robust 
nanoparticles, but is often avoided due to possible undesired side-reactions with the active 
ingredient and the toxicity of the crosslinker agents employed [7, 53]. However, 
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biocompatible crosslinkers like natural di- and tricarboxylic acids have been used to prepare 
biodegradable chitosan nanoparticles by the aid of the water soluble condensation agent 
carbodiimide [11, 54]. The condensation reaction involves the carboxylic groups of the 
natural acids and the amine groups of chitosan.  
Ionic crosslinking 
Ionic crosslinking (also called ionotropic gelation) is usually considered more advantageous 
than covalent crosslinking due to milder conditions and simpler experimental procedures. 
Under appropriate experimental conditions (i.e., suitable pH and dilute concentrations of 
precursor materials), nanoparticles can be prepared by ionically crosslinking 
polyelectrolytes with multivalent ions of opposite charge [11, 52, 53]. Nanoparticles based 
on alginate can for instance be prepared by crosslinking the ionized carboxyl groups on the 
alginate chains with Ca2+-ions in aqueous media [55]. The most widely studied 
nanoparticles prepared by this method are perhaps chitosan nanoparticles crosslinked with 
tripolyphosphate (TPP), which was first reported by Calvo et al. in 1997 [11, 56]. TPP is a 
generally recognized as safe (GRAS) substance by the Unites States Food and Drug 
Administration (FDA) [57] and is negatively charged over a wide pH range. It can thus 
electrostatically interact with the protonated and positively charged amine groups of 
chitosan to form nanogels or nanoparticles. The crosslinking process can also be 
accompanied by other secondary inter-chain interactions, such as hydrogen bonding 
between chitosan’s hydroxyl groups [7]. Parameters that potentially affect preparation of 
nanoparticles by ionic crosslinking includes the ionic strength of the solvent [58], the type 
[11] and molecular weight [59, 60] of polysaccharide, the polysaccharide concentration [61, 
62], the crosslinker to polysaccharide ratio [63, 64], the pH [65, 66], and the mixing 
conditions [67, 68]. Ionically crosslinked nanoparticles can be considered less robust than 
covalently crosslinked nanoparticles, due to differences in bond strength [69]. 
Polyelectrolyte complexation 
Polysaccharides with a polyelectrolyte character can form complexes with oppositely 
charged polymers through intermolecular electrostatic interaction. Chitosan is widely used; 
being one of the few positively charged polysaccharides. Other polysaccharides require 
chemical modification with for example oligo- or polyamines to obtain extensive positive 
charge. A common example of polyelectrolyte complexation is the interaction of chitosan 
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with negatively charged alginate [11]. Chitosan can also form polyelectrolyte complexes 
directly with negatively charged macromolecular drugs, such as nucleic acids [10, 70]. The 
mechanism for particle formation involves non-covalent, electrostatic interactions, but 
nanoparticles prepared by this mechanism may be more robust than ionically crosslinked 
particles due to the large portion of the polysaccharides involved in the complex formation 
[7]. 
Self-assembly 
Polysaccharides with an amphiphilic character can spontaneously form nanoparticles in the 
form of micelles or polymer aggregates in an aqueous environment. The micelle formation 
takes place at concentrations above the critical micellar concentration. The underlying 
mechanism consists of inter and intra molecular associations between hydrophobic parts on 
the polysaccharide chains to minimize the interfacial free energy [11]. The particles can 
exhibit a core-shell structure with a hydrophobic core and a hydrophilic shell. 
Polysaccharides are generally hydrophilic, but can naturally possess some hydrophobic parts 
or be hydrophobically modified to facilitate self-assembly. Chitosan has for instance been 
modified with the long-chained acid linolenic acid to increase the amphiphilic character of 
the polysaccharide [71]. There has been some debate of the suitability of such self-
assembled nanoparticles for drug delivery purposes, due to the possible loss of particle 
integrity upon dilution after administration [72]. 
The nanoparticle preparation may also be a mixture of the different methods. Nanoparticles 
can for instance be prepared by covalent crosslinking and subsequently coated with a 
polysaccharide of opposite charge through polyelectrolyte complexation on the particle 
surface.  
2.2.3 Polysaccharidebasednanoparticlesasdrugdeliverysystems
This work focuses on the polysaccharides chitosan and pectin due to these materials’ 
intrinsic mucoadhesive properties and their ability to form nanoparticles in the presence of 
oppositely charged multivalent ions. Moreover, the difference in polyelectrolyte character of 
chitosan (positive) and pectin (negative) can facilitate incorporation of both negatively and 
positively charged drugs, thus enhancing the versatility of the polysaccharide based 
nanoparticulate DDSs. 
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2.2.3.1 Chitosan and chitosan based nanoparticles 
Chitosan is obtained by deacetylation of the naturally occurring polysaccharide chitin, a 
structural component in the exoskeleton of arthropods and in the cell wall of fungi and yeast 
[17]. The main commercial sources of chitin and chitosan are crab and shrimp shells. 
Chitosan is composed of ȕ-1,4-linked glucosamine and N-acetyl-D-glucosamine units, and 
is mainly characterized by the amount of deacetylated units and by its molecular weight. 
The degree of deacetylation (DDA) usually ranges from 70 to 95%, while the molecular 
weight varies widely from 10 to 1000 kDa [73].  
The pKa value of chitosan has been reported to be approximately 6.3í6.6, and is affected by 
the DDA [17, 74, 75]. Chitosan is thus readily soluble in an acidic environment due to 
protonation of the amine groups and exhibits a polyelectrolyte character in solution. The use 
of acidic solvents can be avoided by utilizing water soluble quaternized or salt derivatives of 
chitosan. Several other derivatives of chitosan have also been synthesized to modulate its 
physical and biochemical properties [17, 76]. Thermosensitive chitosan derivatives have for 
instance been prepared by grafting poly(N-isopropyl-acrylamide) onto the chitosan chains 
[77]. Chitosan can be depolymerized and thermally degraded by hydrolytic cleavage, and is 
enzymatically degraded in the human body by lysozyme and in the colon by bacterial 
enzymes [17, 78].  
Chitosan is generally regarded as biocompatible and biodegradable, exhibiting low 
cytotoxicity [17, 79]. Hence, chitosan is a suitable material for DDSs, but it is far from 
being an inert excipient. It may give an immunogenic response and has, among more, been 
found to exhibit antibacterial, antifungal, antioxidant and anticancer activity [53, 79-81]. 
Moreover, chitosan has mucoadhesive properties and the ability to transiently open tight-
junctions to facilitate paracellular uptake of drugs [17, 76]. Chitosan is highly suitable for 
the delivery of negatively charged macromolecular drugs through mucosal administration 
routes. This is not only due to the possibility of drug encapsulation by electrostatic 
interactions between the positively charged chitosan and the negatively charged drugs, but 
also due to chitosan’s ability to adhere to mucus and transiently opening tight-junctions. 
Chitosan based nanoparticles are perhaps the most widely studied polysaccharide 
nanoparticles. They have been studied for delivery of both low and high molecular weight 
drugs at various administration routes [53, 70, 82]. For instance, Wang et al. studied the 
potential of using nanoparticles composed of the chitosan derivative chitosan-N-acetyl-L-
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cysteine (chitosan-NAC) for systemic administration of insulin through the nasal route. 
They found that intranasal administration of chitosan-NAC nanoparticles in rats enhanced 
the absorption of insulin compared with unmodified chitosan nanoparticles and insulin 
solution [83].  
In a study aiming at direct nose-to-brain targeting of estradiol, Wang et al. found that 
estradiol-loaded chitosan nanoparticles prepared by ionotropic gelation with TPP resulted in 
significantly increased drug levels in the cerebrospinal fluid after nasal administration if 
compared to intravenously administered nanoparticles [84]. Moreover, metronidazole 
containing chitosan nanoparticles for colon-specific delivery was evaluated in vitro by 
Elzatahry and Mohy Eldin and were found to exhibit excellent mucoadhesive properties and 
the ability to control the drug release over a period of 12 hours [85].  
The versatility and positive charge of chitosan nanoparticles render them a natural choice in 
studies on polysaccharide based nanoparticles for potential use as DDSs for mucosal 
administration.  
2.2.3.2 Pectin and pectin based nanoparticles 
Pectin is a class of complex polysaccharides found in the cell wall of higher plants, and is 
widely used in the food industry as gelling and thickening agents. Pectins have a very 
complex and heterogeneous structure and consist primarily of homogalacturonan regions 
composed of repeating alpha-1,4-D-galacturonic acid units [47, 86, 87]. These so-called 
“smooth” regions are attached to “hairy regions” built up by alternating 1,2-linked alpha-D-
galactose and alpha-L-rhamnose units. The hairy regions are highly branched with neutral 
arabinan, galactan and arabinogalactan side chains. Pectins are generally divided into two 
main categories, depending on the degree of methylesterified carboxyl groups (DE): high-
methoxylated pectin (HM-pectin) with a DE above 50%; and low-methoxylated pectin (LM-
pectin) with a DE below 50%. LM-pectin can also be modified by amidation [47], resulting 
in amidated low-methoxylated pectin (AM-pectin). The pKa value of the carboxyl groups of 
pectin is around 3.5 [86], and pectins are thus negatively charged at physiological pH (~7) 
and at most mucosal sites. 
Pectins can be hydrolytically cleaved and degraded by bacterial enzymes in the colon [46, 
87]. Pectins are generally considered biocompatible and biodegradable exhibiting low-
toxicity, but as for chitosan, pectins are not completely inert excipients. They have for 
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instance been shown to exhibit mucoadhesive properties and the ability to target cancer cells 
expressing lectin receptors (which can bind to the galactose rich side chains of pectins) [10, 
46, 47]. It should be noted that pectin was previously considered a poor mucoadhesive [88], 
however, more recent studies indicate the opposite [89-91].   
Pectin nanoparticles are much less studied than chitosan nanoparticles. This may be linked 
to both the abundance of other negatively charged polysaccharides and the fact that pectin 
has a rather complex structure. However, a few promising studies can be mentioned. 
Opanasopit et al. found for instance that ionically crosslinked pectin nanoparticles have 
potential use as safe gene delivery vectors [64]: The plasmid DNA-loaded Ca-pectinate and 
Mg-pectinate nanoparticles prepared had the ability to transfect a human hepatoma cell line 
with low cytotoxicity. In another study by Sharma et al. [92], thiolated pectin nanoparticles 
where found to increase the ex vivo corneal permeation of the encapsulated drug, timolol 
maleate, if compared to a conventional solution dosage form. Moreover, Cheng and Lim 
showed that insulin can be incorporated into pectin nanoparticles crosslinked with calcium 
ions [93]. These particles were proposed for systemic delivery of insulin through the upper 
part of colon, which somewhat resembles the natural delivery route of physiological insulin 
[93]. 
Pectin based nanoparticles are promising DDSs as they, among more, may possess both 
mucoadhesive properties and targeting abilities. As opposed to chitosan nanoparticles, 
pectin based nanoparticles are negatively charged and less extensively studied in the 
literature. These considerations make pectin nanoparticles good candidates for studies on 
polysaccharide based nanoparticles for drug delivery applications.   
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3 Aimofthethesis
In the search for improved drug delivery systems, the understanding of the system’s 
preparation and physicochemical characteristics is essential. Consequently, the overall aim 
of this thesis was to study the possibility to prepare nanoparticles from chitosan and pectin 
by ionotropic gelation and to investigate their physicochemical characteristics and 
properties.  
The specific objectives of the studies were: 
¾ To investigate parameters that can affect the particle preparation and important 
physicochemical properties, such as the particle size, charge and compactness 
¾ To develop a method for the estimation of the compactness of the nanoparticles 
¾ To investigate the stability of the nanoparticles in suspension 
¾ To investigate the potential mucoadhesive properties of the nanoparticles 
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4 Summaryofpapers
4.1 PaperI
This paper describes a method based on the Mie theory for determining the local polymer 
concentration inside spherical nanoparticles (cNP). The method can be used to obtain vital 
information about the compactness of nanoparticles in suspension, i.e., the degree of particle 
swelling. In addition, the method can be used to calculate the number density of the 
particles, the molecular weight of the particles, and (if the number average molecular 
weight, Mn, of the polymer is known) the aggregation number of polymer chains inside the 
nanoparticles (Nagg). The calculations are based on the relationship between the size of the 
nanoparticles and the turbidity of the sample. The method was experimentally tested on 
chitosan nanoparticles prepared by crosslinking chitosan with tripolyphosphate (TPP) in 
aqueous media (0.10 M NaCl). It was found, as expected, that the compactness of the 
particles increased with the crosslinking density (i.e., the TPP concentration). 
4.2 PaperII
In this paper, several combinations of chitosan nanoparticles were prepared by ionotropic 
gelation of chitosan with TPP in aqueous media. The effects of the ionic strength of the 
solvent (0, 0.05 and 0.15 M NaCl) employed in the particle preparation on the average size 
and compactness of the particles were investigated. In addition, the effects of the chitosan 
chloride concentration (0.05 and 0.10%) and the crosslinker to polysaccharide ratio (5:95, 
10:90, 15:85 and 20:80) on the particle characteristics were studied. The chitosan-TPP 
nanoparticles were characterized by dynamic light scattering, zeta potential, and turbidity 
measurements. The compactness of the nanoparticles was estimated by using the method 
reported in paper I.  
All the investigated preparation parameters, i.e., the ionic strength of the solvent, the 
chitosan concentration and the TPP to chitosan ratio, affected the particle characteristics. If 
compared to particles prepared in pure water, smaller and more compact particles were 
formed in the presence of sodium chloride. It was also observed an increase in the average 
particle size with an increase in the chitosan concentration, however, only moderate changes 
in the average particle size were found with increasing TPP to chitosan ratios. The particle 
compactness increased with higher solvent salinity and TPP to chitosan ratios, while no 
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differences in the compactness of the particles prepared at low and high chitosan 
concentration were observed when a moderate amount of TPP was employed. 
4.3 PaperIII
In this paper, the physical stability of chitosan nanoparticles crosslinked with TPP was 
investigated over a period of one month. Special emphasis was placed on changes in the 
particle size and the particle compactness. The chitosan-TPP particles were prepared at 
different ionic strengths (0, 0.05 and 0.15 M NaCl), chitosan chloride concentrations (0.05 
and 0.10%) and TPP to chitosan ratios (5:95, 10:90, 15:85 and 20:80). In the presence of 
monovalent salt, the positive zeta potential of the particles was reduced. In spite of this, the 
particles were more stable when prepared and stored under saline conditions compared to 
pure water. This could be attributed to the smaller particle sizes found in the presence of 
sodium chloride. Most of the particles prepared in saline solvents were stable with respect to 
changes in the size and the compactness of the particles. However, instability was observed 
at the highest crosslinker to polysaccharide ratios. Generally, a reduction in the zeta 
potential and an increase in the particle compactness were observed at increasing TPP to 
chitosan ratios (paper II). This combined with the size increase induced by a high 
concentration of chitosan, increased the aggregation and sedimentation tendency of the 
particles and reduced the colloidal stability of these particles. 
4.4 PaperIV
In this paper, nanoparticles were prepared by ionotropic gelation of low-methoxylated (LM) 
and amidated low-methoxylated (AM) pectin with zinc chloride (ZnCl2) in aqueous media. 
The samples were characterized by atomic force microscopy, dynamic light scattering, 
turbidimetry, zeta potential and pH measurements. Negatively charged pectin nanoparticles 
could be prepared at a pectin concentration of 0.07% and a ZnCl2 to pectin ratio of 15:85 in 
the presence of sodium chloride (0.05 M), but not in pure water. Interestingly, particles in 
the nanometer size-range could also be prepared in the absence of the crosslinker ZnCl2. 
The AM-pectin nanoparticles were much less polydisperse than the LM-pectin 
nanoparticles, and hence considered more promising as a potential drug delivery system.  
Further studies were performed to investigate the colloidal stability and the effect of the 
pectin concentration on the size, charge and compactness of the AM-pectin nanoparticles. 
These studied showed that the self-associated AM-pectin nanoparticles (prepared in the 
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absence of ZnCl2) were stable for one month of storage, while the crosslinked AM-pectin 
nanoparticles were stable for one week. This difference in colloidal stability could be 
attributed to the reduced absolute zeta potential values of the crosslinked nanoparticles. 
Increasing AM-pectin concentrations from 0.03 to 0.07% resulted in a size increase of the 
self-associated nanoparticles, but not of the crosslinked nanoparticles. This lack in size 
increase was connected with an increase in particle compactness of the crosslinked 
nanoparticles with increasing AM-pectin concentrations.  
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5 Experimentalconsiderations
Experimental considerations and descriptions of the main materials and methods used in 
papers I-IV are given in this section. Further details can be found in the individual papers. 
The in vitro interaction studies between two selected nanoparticle formulations and mucin 
are, however, only described herein.  
5.1 Materials
Both chitosan and pectin possess mucoadhesive properties and the ability to gel in the 
presence of multivalent ions of opposite charge. However, chitosan is positively charged 
(below pH ~6.5) and a rather well-studied polysaccharide for preparation of nanoparticles, 
while pectin is negatively charged (above pH ~3.5) and much less studied. These 
considerations formed the basis for the choice of pectin and chitosan for preparation of 
nanoparticles with potentially similar, yet different properties.  
Table 5.1 – Materials 
Mw = Weight average molecular weight; Mn = Number average molecular weight; DDA = Degree of 
deacetylation; DE = Degree of esterification; DA = Degree of amidation; GalA = Galacturonic acid; Rha = 
Rhamnose 
* % of total carbohydrate content (data published by Smistad et. al [94]) 
# simplified structure, see [94]and section 2.2.3.2 for a more comprehensive description of the pectin structure 
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An overview of the types of polysaccharides and crosslinkers used in the different papers 
are given in Table 5.1.  
The hydrochloride salt of chitosan was chosen because it is embedded in the European 
Pharmacopeia and water soluble. Moreover, chitosan with a high DDA (83%) was used to 
ensure sufficient protonation and interaction with the anionic crosslinker. The crosslinker 
salt chosen for preparation of chitosan nanoparticles was the pentasodium salt of 
tripolyphosphate, which is generally recognized as safe by the FDA [57].  
Pectin with low DE was chosen since this type can easily gel in the presence of divalent 
cations [46, 95]. An amidated form of low-methoxylated pectin was also included to 
potentially adjust the properties of the nanoparticles prepared. Zinc ions have been applied 
as an alternative to calcium ions in the preparation of macroscopic pectin gels [91] and can 
also be used as an active ingredient, for instance in the treatment of bad breath [96]. The 
crosslinker chosen for the preparation of ionically crosslinked pectin nanoparticles was 
therefore zinc chloride.  
Table 5.2 – Overview of parameters used in the particle preparation 
PS = Polysaccharide; CL = Crosslinker; NP = Nanoparticle ; TPP = Tripolyphosphate 
Paper

Typeof
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Typeof
CL
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
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time
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5.2 Methods
5.2.1 Particlepreparationbyionotropicgelation
Ionotropic gelation by crosslinking charged polymer chains with oppositely charged 
multivalent ions is a simple and fast technique for the preparation of nanoparticle 
dispersions. In this thesis, the ionotropic gelation was performed by adding a fixed amount 
of crosslinker solution drop-wise to a fixed amount of dilute polysaccharide solution under 
magnetic stirring (see illustration in Figure 5.1). The speed of crosslinker addition (pump 
speed = 25 rpm), the size of the magnetic bar (20 × 6 mm) and the magnetic stirring speed 
(550 rpm) were kept constant in all papers. The particles were prepared at different 
polysaccharide concentrations in water with varying amounts of sodium chloride, and at 
different crosslinker to polysaccharide ratios, as given in Table 5.2. The pectin nanoparticles 
were only prepared at a sodium chloride concentration of 0.05 M because the preliminary 
results (performed on LM-pectin) at high concentrations (0.15 M) were unsatisfactory. The 
batch size (and the vial size) might affect the stirring conditions and thus also the properties 
of the nanoparticles. The batch size in papers II-IV was therefore kept constant to better 
compare the different particles prepared, and accordingly the amounts of crosslinker 
solution (15 g) and polysaccharide solution (60 g) prior to mixing were also kept constant. 
Borosilicate glass vials for injection were used in all papers (50 mL in paper I; 100 mL in 
papers II-IV). It should be noted that the tubing used in paper IV had a wider inner diameter, 
resulting in a faster addition of the crosslinker solution (approximately 8 g/min vs. 3.5 g/min 
in papers I-III), which might affect the crosslinking process.  
 
Figure 5.1 – Schematic illustration of the particle preparation. 
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5.2.2 Dynamiclightscattering
Dynamic light scattering is a non-invasive and well-established technique for measuring 
size and size distributions of particles in the submicron region, and can also be used to study 
the behavior of complex fluids, such as concentrated polymer solutions. A schematic 
illustration of the passage of light in DLS experiments is given in Figure 5.2.  
 
Figure 5.2 – Schematic illustration of the passage of light in DLS experiments. 
The principle of DLS size measurements relies on the fact that the Brownian motion of 
suspended particles will cause time dependent fluctuations in the intensity of the scattered 
light. These fluctuations are recorded at different scattering angles (ș) or wave vectors (q) 
and expressed in terms of autocorrelation functions. The wave vector is defined as 
q=4ʌnsin(ș/2)/ȜL, where ȜL is the wavelength of the incident light in vacuum, ș is the 
scattering angle, and n is the refractive index of the sample. Assuming that the scattering 
field obeys Gaussian statistics, the experimentally measured homodyne intensity 
autocorrelation function g2(q,t) in DLS measurements is directly linked to the theoretically 
amenable first-order electric field autocorrelation function, g1(t), through the Siegert 
relationship [97]: 212 )(1),( tgBtqg += , where B ( 1) is an instrumental parameter and t 
is the time. The mean relaxation time (Ĳf) and the mutual diffusion coefficient (D) of the 
particles can be derived from the autocorrelation functions. Assuming that the particles are 
compact spheres, the mean hydrodynamic radius, Rh, of the particles can be calculated from 
D using the Stokes-Einstein relationship: 
D
TkR Bh πη6
=  
where kB is the Boltzmann constant, T is the absolute temperature, and Ș is the viscosity of 
the solvent at the given temperature. 
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In this thesis, two different light scattering instruments were used: an ALV/CGS-8F 
Compact Goniometer System from ALV-GmbH, Germany (papers I-IV), and a Zetasizer 
Nano NZ from Malvern Instruments Ltd., UK (paper IV). The ALV-goniometer is equipped 
with a 22 mW He-Ne-laser, operating at a wavelength of 632.8. The intensity of the 
scattered light can be measured at 8 different angles simultaneously, and any angular 
dependency of the calculated Rh can thus easily be checked. The Zetasizer Nano NZ is 
equipped with a 4 mW He-Ne-laser (operating at a wavelength of 632.8) and uses non-
invasive back-scattering detection at a fixed angle of 173°. The fixed detection angle 
precludes the control of any angular dependency of the calculated Rh. 
In papers I-IV, the g1(t) functions obtained from the ALV goniometer were fitted to a 
stretched exponential function [ ]βτ )/(exp)(1 fettg −= , where Ĳfe is an effective relaxation 
time and ȕ is a fitting parameter (0 < ȕ  1). The value of ȕ gives an indication of the 
distribution width of the relaxation times and thus the size distribution (monodisperse 
samples have a ȕ value close to 1). The mean relaxation time (Ĳf) was calculated through the 
following relationship: ββ
τ
τ
1Γ= fef , where Ƚ(1/ȕ) is the gamma function. In all papers, the 
relaxation times were found to be diffusive (Ĳf ~ q-2), and the mutual diffusion coefficients 
were thus obtained from the following expression: D = 1/(Ĳf q2). Finally, the apparent, mean 
Rh of the particles was calculated using the Stokes-Einstein relationship given above. The 
average Rh values reported were obtained by calculating the arithmetic mean of multiple 
measurements (n = 3-4) on the same batch. 
In paper IV, the ALV goniometer was primarily used on representative samples to check the 
angular dependency of the Rh and to confirm that Ĳf ~ q-2. The Rh and polydispersity index 
(PDI) values reported in paper IV were thus obtained from experiments performed on the 
Zetasizer Nano NZ. The general purpose fitting method in the Zetasizer software was 
chosen for the calculation of the mean Rh values, since this fitting method gives values that 
are comparable to the ones obtained from experiments on the ALV goniometer [98]. The 
mean Rh value of each batch was calculated from multiple measurements (n > 3) by the 
Zetasizer software. The average Rh values reported were obtained by calculating the 
arithmetic mean of separate batches (n = 2-3). The PDI is a measure of the size distribution 
with values in the range 0 to 1. Monodisperse samples have a PDI value less than 0.1, while 
PDI values greater than 0.7 indicate a very broad size distribution. 
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5.2.3 Zetapotentialmeasurements
The zeta potential is a common measure of the magnitude of the electrostatic charge of 
particles in dispersion, and is highly relevant in stability studies of nanoparticle suspensions. 
Generally, zeta potentials above an absolute value of 30 mV are considered necessary to 
ensure good colloidal stability [99-101]. 
Charged particles in aqueous dispersion are surrounded by ions in an electric double layer. 
This liquid double layer consists of an inner region (Stern layer) with relatively strongly 
bound counter-ions, and an outer region with less firmly associated ions. The zeta potential 
is the electric potential at the slipping plane (see Figure 5.3), i.e., at the surface of the 
stationary liquid double layer. 
 
Figure 5.3 – Schematic illustration of a negatively charged particle in aqueous media 
Zeta potential measurements on particle dispersions are commonly performed by 
electrophoresis, which is based on the migration of charged particles when exposed to an 
electric field. The velocity of the migrating particles can be measured by Laser Doppler 
velocimetry, in which the frequency shift or phase shift of an incident laser beam caused by 
the moving particles is used to calculate the electrophoretic mobility, UE, of the particles. 
The zeta potential (ɺ) can then be calculated from the Henry equation: 
)(
3
2 KafU E η
εζ
=  
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where Ș and İ are the viscosity and the dielectric constant, respectively, of the solvent at a 
given temperature. The Smoluchowski approximation to Henry’s function (f(Ka) = 1.5) was 
applied in all papers (II-IV). 
In this thesis, two similar instruments measuring the zeta potential by electrophoresis and 
Laser Doppler velocimetry were used (both from Malvern Instruments Ltd., UK): Malvern 
Zetasizer 3000HSA (papers II and III) and Zetasizer Nano NZ (paper IV).  
5.2.4 Turbiditymeasurements
Turbidity is a measure of a sample’s ability to hinder the passage of light. Consequently, the 
turbidity of a nanoparticle dispersion is affected by the number and the size of the particles 
present, and by the difference in refractive index between the particles and the solvent. 
Turbidity measurements can be conducted by the means of a spectrophotometer. In contrast 
to DLS measurements, where the scattered light intensity is detected, it is the transmitted 
light intensity that is detected in turbidity measurements. The turbidity can be calculated 
using the following expression (Lambert-Beer’s law): 
¸¸¹
·
¨¨©
§
−=
0
ln1
I
I
L
tτ  
where L is the light path length in the sample cell, It is the intensity of the light transmitted 
through the sample, and I0 is the intensity of the light transmitted through the solvent.  
In this thesis, a temperature controlled Helios Gamma spectrophotometer from Thermo 
Spectronic, UK, was used for the turbidity measurements. 
5.2.5 Determinationoftheparticlecompactness
The determination of the compactness of nanoparticles in suspension, or the degree of 
particle swelling, can be difficult to perform experimentally. In paper I, a theoretical method 
was developed to overcome these difficulties. The method combines data from DLS and 
turbidity measurements to calculate the local polymer concentration inside nanoparticles, 
cNP, which can be used as a measure of the particle compactness. Accordingly, increasing 
cNP values correspond to higher particle compactness. 
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The cNP can be calculated through the following expression (paper I):  
( ) ( )( ) »»¼
º
««¬
ª
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where Ĳ is the turbidity of the nanoparticle suspension, Rh is the hydrodynamic radius of the 
particles, ct is the total polymer concentration in suspension, and 
0
)/(4
n
dcdnRw
T
h
λ
π
= , where 
n0 is the refractive index of the solvent, ȜT is the wave length at which the turbidity 
measurements were performed, and dn/dc is the refractive index increment of the polymer. 
The method is developed for spherical, monodisperse particles, and the total polymer 
concentration that exists in the form of nanoparticles must be known. These considerations 
could be assumed for the crosslinked nanoparticles prepared in the presence of sodium 
chloride, since Ĳf ~ q-2 indicated spherical particles, and since the relatively high crosslinker 
concentrations and ionic strength promoted polysaccharide aggregation and narrow size 
distributions (paper II and IV). It should be noted that the method is not suitable for the 
estimation of the cNP of core-shell nanoparticles with distinctly different refractive indices of 
the core and shell, since such particles will exhibit a more complex scattering profile. 
5.2.6 Interactionstudieswithmucin
In order to evaluate the nanoparticles’ potential mucoadhesive properties, an in vitro 
interaction test with mucin1 was performed on two nanoparticle formulations, one made 
from chitosan and one made from AM-pectin. The nanoparticles chosen were prepared in 
0.05 M NaCl at a crosslinker to polysaccharide ratio of 15:85 (w:w) and at a polysaccharide 
concentration of 0.05% (w/w). 
The method reported by Klemetsrud et al. [98] was used, with small modifications. Shortly, 
5 mL of a 0.10% (w/w) solution of mucin in 0.05 M NaCl was added drop-wise to 10 mL of 
nanoparticle suspension under magnetic stirring. The resultant mixtures were evaluated 
visually and, if suitable, by DLS, turbidity and zeta potential measurements the following 
day. Controls were prepared by mixing the mucin solution and the nanoparticle suspensions 
with 10 and 5 mL of 0.05 M NaCl, respectively. 
                                                 
1 Water soluble mucin from bovine submaxillary glands, type I-S, used as received (Sigma-Aldrich, USA). 
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6 Mainresultsanddiscussion
6.1 Preparationofnanoparticles
The first objective of this study was to investigate parameters affecting the preparation of 
nanoparticles based on the polysaccharides chitosan and pectin. The nanoparticle 
preparation method chosen was ionotropic gelation, which is considered a simple and mild 
technique suitable for scaling up [53, 68]. To assure formation of nanoparticles, the 
ionotropic gelation should be performed at dilute polysaccharide concentrations [52], 
avoiding extensive polymer chain overlap  and hence formation of larger particles or a 
macroscopic gel. The conformation and the extent of chain overlap of polysaccharides in 
solution are dependent on the type and concentration of polysaccharide, the solvent 
properties and the thermodynamic conditions. For the polyelectrolytes chitosan and pectin, 
the conformation in aqueous media is naturally dependent on their pKa values and the pH. 
At a pH supporting ionization of the amine and carboxyl groups on chitosan and pectin, 
respectively, the polysaccharide chains will have an extended conformation in pure water 
due to charge repulsion between the ionized groups [87, 102]. 
 
Figure 6.1 – Proposed conformation of charged polysaccharide chains in (a) pure water, and (b) 0.05 M 
NaCl, and crosslinked polysaccharide chains in (c) water and (d) 0.05 M NaCl. Junction zones are given 
in red. 
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The easiest way to minimize the overlap between the polysaccharide chains is to reduce the 
polysaccharide concentration below the overlap concentration. The major drawback of 
doing this is that the total batch volume will increase with respect to the amount of particles 
formed. This may pose problems considering both the sensitivity limitations in the 
characterization techniques and an eventual up-scale of the particle preparation. This is 
especially the case if working with charged polyelectrolytes in pure water, having an 
extended conformation in solution.  
Another way of reducing the extent of overlap of the polysaccharide chains is to add 
monovalent salt. Monovalent salts present in sufficient amounts can reduce the electrostatic 
repulsion between the charged groups, thus promoting contraction of the polysaccharide 
chains and reduced chain overlap [103]. In this way, a smaller total batch volume will be 
required to obtain the same amount of nanoparticles. Furthermore, if the particles are 
prepared at an ionic strength similar to that of physiological fluids they are more likely to 
maintain their integrity when administered to the patient. Increasing the ionic strength 
during the particle preparation can, however, be a drawback in cases where a significant 
ionic interaction between the carrier and the encapsulated substances is required during the 
particle preparation. A schematic representation of the proposed conformation of charged 
polysaccharide chains in pure water and in the presence of 0.05 M NaCl is given in Figure 
6.1, along with the proposed effects on the ionic crosslinking process.  
  
 Figure 6.2 – The average Rh of chitosan nanoparticles one day after particle preparation. Connection 
lines between the symbols are given in order to guide the eyes. Samples in which particle sedimentation 
was observed are omitted from the figure. The standard deviations of Rh are equal to or smaller than the 
size of the symbols. 
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In paper II and IV, the preparation of ionically crosslinked chitosan (paper II) and pectin 
(paper IV) nanoparticles was investigated in detail. With the effects on the polysaccharide 
conformation kept in mind, it was initially hypothesized that the nanoparticle preparation 
would be greatly affected by the ionic strength of the solvent. Additionally, two preparation 
parameters that were both easily adjustable and likely to affect the particle characteristics 
were investigated: the polysaccharide concentration [61, 62, 67] and the crosslinker to 
polysaccharide ratio [60, 62, 64].  
Preliminary experiments indicated that the formation of pectin nanoparticles was more 
sensitive to changes in the preparation parameters than the chitosan nanoparticles. 
Accordingly, different experimental set-ups for the preparation of the chitosan and the 
pectin nanoparticles were chosen. The main differences in the preparation parameters were 
the sodium chloride concentration and the crosslinker to polysaccharide ratio, which were 
varied in the paper on chitosan nanoparticles (paper II), but kept constant in the paper on 
pectin nanoparticles (paper IV). Moreover, the effect of chitosan concentration was 
investigated in paper II, while the pectin concentration was (initially) kept constant in paper 
IV. 
It was found that chitosan particles in the nanometer size range could be prepared in the 
presence of sodium chloride (see Figure 6.2). In pure water, however, the chitosan particles 
formed were mostly microparticles, and at high chitosan and crosslinker concentrations 
large aggregates that immediately sedimented were formed rather than the desired  
 
Figure 6.3 – The average Rh of self-associated and crosslinked pectin nanoparticles at a concentration of 
0.07% pectin one day after particle preparation. The PDI values are also given. 
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nanoparticles. In the study on pectin particles (paper IV), a partially crosslinked, 
macroscopic polymer network was formed in pure water, while in the presence of sodium 
chloride both non-crosslinked and crosslinked nanoparticles were formed (see Figure 6.3). 
The self-association of pectin into nanoparticles in the presence of monovalent anions and 
cations can be seen in the atomic force microscopy (AFM) images given in Figure 6.4.  The 
self-association can be due to promotion of hydrogen bonding or hydrophobic associations 
[87, 95] at higher ionic strengths. 
From the studies performed in paper II and IV it can be concluded that nanoparticles based 
on chitosan and pectin can be prepared by ionotropic gelation in the presence of sodium 
chloride, which assumingly reduce the extent of polysaccharide chain overlap and promotes 
formation of small crosslinked nanoparticles rather than large clusters or a macroscopic 
polymer network. A more comprehensive presentation of the effects of the preparation 
parameters on the physicochemical characteristics of the nanoparticles is given in the 
following section. 
 
Figure 6.4 – AFM images of dried LM- and AM-pectin samples in 0.05 M NaCl, at a pectin 
concentration of 0.07%, with and without ZnCl2. The images were obtained by scanning in lines (fast 
scanning direction) from the bottom to the top (slow scanning direction), as indicated by the arrows. 
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6.2 Particlecharacteristics
One of the major objectives in this thesis was to characterize the nanoparticles’ 
physicochemical properties, with special emphasis on particle size, charge and compactness. 
These properties may influence the nanoparticles’ suitability as a drug delivery system, as 
already mentioned in the Introduction section. The particles prepared in this thesis were 
composed of two different polysaccharides and varied in size, charge and compactness, thus 
giving a decent platform for further studies on their suitability as drug delivery systems. The 
main observations and differences found for the nanoparticles prepared are presented in the 
following three sub-sections. The results presented were obtained one day after particle 
preparation, unless otherwise described. 
6.2.1 Sizeandsizedistribution
Preliminary experiments indicated that the particle preparation of pectin nanoparticles was 
rather sensitive to the ionic strength and the crosslinker concentration. Therefore, the pectin 
nanoparticles were prepared at fixed sodium chloride and crosslinker concentrations. The 
chitosan nanoparticles could, however, be prepared in a broad range of sodium chloride 
concentrations and crosslinker to chitosan ratios.  
In Figure 6.2 (page 32) one can clearly observe that the presence of monovalent salt reduced 
the size of the chitosan particles from micrometers to nanometers in diameter. As discussed 
in section 6.1, this can be explained by a reduction in the electrostatic repulsion between the 
polymer chains leading to a contracted conformation in solution prior to crosslinking. As 
can be seen in Figure 6.5, the size of the chitosan nanoparticles was not significantly 
affected by an increase in the sodium chloride concentration up to 0.10 M. However, upon 
further increase to an isotonic concentration of 0.15 M NaCl the particle size increased 
slightly. It has previously been shown that an increase in the ionic strength of the media 
favors inter-chain association of chitosan molecules in solution [104], which may explain 
the observed size increase. The observed raise in the number of polymer chains inside the 
nanoparticles (Nagg) with an increase in the sodium chloride concentration (paper II) 
supports this explanation. It should be noted that the batch size of the nanoparticle 
dispersions prepared at 0.10 M NaCl was smaller than the ones prepared at 0.05 and 0.15 M 
NaCl, which may have affected the particle characteristics slightly. A reduced batch size, 
but constant stirring conditions, induces higher sheer stress on the system which can both 
reduce and increase the aggregation tendency of polymers during the crosslinking process 
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[105, 106], and it is hence difficult to conclude if the reduction in batch size can explain the 
slightly smaller sizes observed. 
The ȕ values obtained from the DLS measurements give an indication of the distribution 
width of the relaxation times and thus the particle size distributions (monodisperse samples 
have a ȕ value close to 1). The ȕ values obtained for the particles studied in paper II were 
significantly higher at 0.15 M NaCl if compared to 0.05 M NaCl, which means that an 
increase in the ionic strength resulted in narrower particle size distributions. Since a narrow 
size distribution is of great importance in the development of a drug delivery system, the 
particles prepared at high sodium chloride concentrations may be preferred. Moreover, it 
can be beneficial that the particles are prepared at physiological ionic strengths, which may 
reduce the loss of particle integrity after administration, as already mentioned in section 6.1. 
Thus, the chitosan particles prepared at the isotonic salt concentration of 0.15 M NaCl may 
be preferred in future studies on chitosan nanoparticles for possible drug delivery 
applications. 
 
Figure 6.5 – The average Rh of chitosan nanoparticles prepared at three different TPP to chitosan ratios 
as a function of the NaCl concentration. Connection lines between the symbols are given in order to 
guide the eyes. The deviations of Rh are approximately within the size of the symbols. 
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The effects of the chitosan concentration on the average Rh of chitosan nanoparticles 
prepared in the presence of sodium chloride are given in Figure 6.6. As can be seen from the 
figure, the particle size goes through a maximum with increasing crosslinker to chitosan 
ratios at a high chitosan concentration. In contrast, at a low chitosan concentration, no 
effects on the particle size were observed at low to moderate TPP to chitosan ratios, but a 
small drop in the particle size was observed at the highest ratio (Figure 6.6). In the 
crosslinking process, two opposing mechanisms are occurring simultaneously: 1) inter-
crosslinking between different polymer chains and entities supporting a size increase, and 2) 
intra-crosslinking within the same polymer coil or particle leading to particle contraction 
and a size decrease. The variations in the particle size with increasing TPP to chitosan ratios 
may thus be explained by a sensitive relationship between these two mechanisms, which in 
some cases lead to a net cancellation and a constant particle size and in other cases a small 
decrease or increase in the particle size (Figure 6.6). It was also observed a tendency 
towards narrower particle size distributions (higher ȕ values) with increasing TPP to 
chitosan ratios. 
The average Rh of the chitosan nanoparticles prepared were smaller (approximately 70 to 
220 nm) than the self-associated and the crosslinked pectin nanoparticles (approximately 
230 to 360 nm), see Figure 6.6 and Figure 6.3, respectively.  
  
Figure 6.6 – The average Rh of chitosan nanoparticles prepared in the presence of NaCl as a function of 
TPP to chitosan ratio. Connection lines between the symbols are given in order to guide the eyes. The 
standard deviations of Rh are equal to or smaller than the size of the symbols. 
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Moreover, the particles based on LM-pectin were smaller than the ones based on AM-
pectin. This may be due to the fact that the AM-pectin used had a higher Mw than the LM-
pectin, promoting enhanced polymer chain entanglements and a size increase. Gan et al. 
[61] found for instance in their work on ionically crosslinked chitosan nanoparticles that an 
increase in the molecular weight of the polysaccharide resulted in formation of larger 
particles. However, the chitosan nanoparticles prepared in this work were smaller than the 
pectin nanoparticles (compare Figure 6.6 and Figure 6.3), despite the considerably higher 
Mw of chitosan. This can indicate two things, firstly that the pectin has a higher tendency of 
inter-chain association by other mechanisms than polymer chain entanglements (possibly 
hydrophobic associations of the methoxyl-esterified carboxyl groups), and secondly that the 
chitosan nanoparticles are more densely packed than the pectin nanoparticles. The results 
presented in section 6.2.3 on the effects on the particle compactness can verify the latter 
hypothesis. 
Similar to the ȕ value, the PDI value (ranging from 0 to 1) gives a measure of the particle 
size distribution. The major practical difference is that high PDI values correspond to wide 
size distributions in stead of narrow distributions. In the studies on pectin nanoparticles it 
was found that the self-associated LM-pectin nanoparticles had a bimodal size distribution, 
and an apparent PDI value close to 1. In contrast, the crosslinked LM-pectin nanoparticles 
had a unimodal size distribution and a PDI value of approximately 0.6. Both the self-
associated and the crosslinked AM-pectin nanoparticles had unimodal size distributions and 
lower PDI values (§ 0.3) when compared to the LM-pectin nanoparticles. If analyzing the 
DLS data in paper IV in the same manner as for the chitosan nanoparticles, the ȕ value 
obtained was approximately 0.9. This means that a PDI value of 0.3 corresponds to a ȕ 
value of approximately 0.9. Consequently, the AM-pectin nanoparticles and the chitosan 
nanoparticles prepared at the same sodium chloride concentration (0.05 M) exhibited similar 
size polydispersities, with the chitosan nanoparticles exhibiting ȕ values in the range 0.85-
0.94 and the AM-pectin nanoparticles an approximate ȕ value of 0.9. 
In paper II, it was found that larger particles were formed at a concentration of 0.10% 
chitosan if compared to 0.05%. This was observed at all ionic strengths and TPP to chitosan 
ratios studied. This concentration-induced size increase has been reported in several 
previous studies on chitosan-TPP nanoparticles [61-63, 67] and was expected given the 
greater likelihood of contact between polysaccharide chains at higher concentrations. 
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Of the two different types of pectin, AM-pectin was considered more promising due to the 
narrower particle size distributions observed. Further studies on the effects of the AM-pectin 
concentration on the particle characteristics were therefore performed. Figure 6.7 depicts the 
average Rh of the self-associated and the crosslinked AM-pectin nanoparticles as a function 
of AM-pectin concentration.  From the figure it can be observed an increase in the particle 
size of the self-associated AM-pectin nanoparticles with increasing pectin concentrations. 
This is in agreement with the above mentioned enhancement in inter-chain interactions and 
aggregation tendency at higher polymer concentrations. The particle size of the crosslinked 
AM-pectin nanoparticles, however, was slightly reduced when the pectin concentration 
increased from 0.03% to 0.05%, but found to be constant upon further increase to 0.07% 
pectin. Such peculiar effects on the particle size were also observed for the chitosan 
nanoparticles at increasing TPP to chitosan concentrations, and accordingly, the findings 
can be explained by a sensitive relationship between the two opposing crosslinking 
mechanisms occurring, i.e., intra-particle and inter-particle  crosslinking. No significant 
differences in the PDI values of the AM-pectin nanoparticles were observed in the AM-
pectin concentration range studied (PDI § 0.3; corresponding to a ȕ value of approximately 
0.9). 
To summarize the above: both the chitosan and the pectin nanoparticles prepared in the 
presence of sodium chloride were in the nanometer size range, and the results demonstrate 
the possibility of adjusting the particle size and size distribution by changing either the type 
of polysaccharide, the polysaccharide concentration, the ionic strength of the solvent and/or 
the crosslinker to polysaccharide ratio applied in the particle preparation. 
 
Figure 6.7 – The average Rh of self-associated and crosslinked AM-pectin nanoparticles as a function of 
AM-pectin concentration. Connection lines between the symbols are given in order to guide the eyes. The 
ZnCl2 to pectin weight ratio was 15:85. 
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6.2.2 Charge
As can be seen from Figure 6.8, all the chitosan nanoparticles were positively charged, 
which is in accordance with several previous studies on chitosan-TPP nanoparticles [58, 60, 
107, 108]. In contrast to the positively charged chitosan nanoparticles, the self-associated 
and the crosslinked pectin nanoparticles were negatively charged (see Figure 6.9). The pH 
of the dispersions were around or below the pKa value of the amine groups of chitosan 
(~6.5), and around or above the pKa value of the carboxyl groups of pectin (~ 3.5), thus 
stimulating ionization and the observed positive and negative zeta potentials, respectively.  
The TPP anions will, as a result of the crosslinking process, neutralize some of chitosan’s 
positive charges. An increase in the TPP to chitosan ratio was thus expected to reduce the 
average zeta potential values of the chitosan particles, and this was clearly observed for the 
particles prepared in pure water (see Figure 6.8). In the presence of sodium chloride, 
however, this effect was rather moderate in comparison. Moreover, at low to moderate TPP 
to chitosan ratios, a significant decrease in the zeta potential values was observed if 
prepared in the presence of sodium chloride (with respect to pure water). These results are 
in accordance with the proposed salt-induced screening of the electrostatic charges and are 
also in agreement with the findings of Huang and Lapitsky [58] in their recent study on 
chitosan-TPP nanoparticles. 
 
Figure 6.8 – The average zeta potential of chitosan nanoparticles as a function of TPP to chitosan ratio. 
Connection lines are given in order to guide the eyes. Samples in which particle sedimentation was 
observed are omitted from the figure. The points without error bars have standard deviations equal to or 
smaller than the size of the symbols.  
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The crosslinked pectin nanoparticles exhibited lower absolute zeta potential values than the 
self-associated nanoparticles (Figure 6.9). This is in accordance with the proposed 
crosslinking mechanism where the positively charged divalent Zn2+-ions electrostatically 
interact with negatively charged carboxyl groups, thus reducing the amount of charged 
species and the absolute value of the particles’ zeta potential.  
  
Figure 6.9 – Left: The average zeta potential values of self-associated and crosslinked LM-pectin and 
AM-pectin nanoparticles prepared at 0.07% pectin. Right: The average zeta potential values of self-
associated and crosslinked AM-pectin nanoparticles as a function of AM-pectin concentration 
(connection lines between the symbols are given in order to guide the eyes). The ZnCl2 to pectin weight 
ratio was 15:85.  
6.2.3 Compactness
The work performed in paper I describes a theoretical method for the calculation of the local 
polymer concentration inside nanoparticles (cNP) by combining data from size and turbidity 
measurements. This work enabled the calculation of the cNP as a measure of the particle 
compactness in the following papers II-IV. Increasing cNP values correspond to higher 
particle compactness. 
Figure 6.10 depicts the local polymer concentrations inside the chitosan nanoparticles (cNP) 
studied in paper II as a function of the TPP to chitosan ratio. At moderate to high TPP to 
chitosan ratios, a distinct increase in the cNP was observed with an increase in the sodium 
chloride concentration. This relates well with the proposed charge screening effect of 
monovalent salts and the resultant polymer conformation change illustrated in Figure 6.1 
(page 31). As expected, a marked increase in the cNP was also found with increasing TPP to 
chitosan ratios, whereas the cNP was found to be unaffected by the chitosan concentration at 
low to moderate TPP to chitosan ratios. Interestingly, at the highest TPP to chitosan ratio of 
20:80, the cNP increased when adjusting the chitosan concentration from 0.05% to 0.10%.  
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Figure 6.10 – Left: The local polymer concentration inside chitosan nanoparticles as a function of TPP 
to chitosan ratio. Samples in which particle sedimentation was observed are omitted from the figure. 
Right: The local polymer concentration inside crosslinked AM-pectin nanoparticles as a function of AM-
pectin concentration. The ZnCl2 to pectin weight ratio was 15:85. Connection lines between the symbols 
are given in order to guide the eyes. 
This observation can be explained by an ionic strength effect: changing the chitosan 
concentration while keeping the TPP to chitosan ratio constant will naturally lead to an 
increase in the TPP concentration, and thus the ionic strength of the solution. At some point, 
this contribution to the ionic strength may enhance the contraction tendency of the chitosan, 
resulting in higher cNP values. 
For the pectin nanoparticles studied in paper IV, the cNP was estimated for the crosslinked 
AM-pectin nanoparticles prepared at 0.05 M NaCl and a ZnCl2 to pectin ratio of 15:85. The 
cNP values of these particles as a function of the AM-pectin concentration are given in 
Figure 6.10. Interestingly, as can be seen in the figure, increasing AM-pectin concentrations 
lead to increasing cNP values. As mentioned above, this may be an effect induced by the 
proportional increase in the ZnCl2 concentration with increasing pectin concentrations, 
leading to higher ionic strengths and an enhanced salting-out effect or contraction of the 
polymer entities in solution.  
The chitosan nanoparticles were generally found to be more compact (higher cNP values) 
than the AM-pectin nanoparticles, and can partly explain why the chitosan nanoparticles 
were found to be smaller than the pectin nanoparticles, as already presented in section 6.2.1. 
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6.3 Stabilityinsuspension
The results presented in sections 6.1 and 6.2 clearly illustrate the potential and benefits of 
preparing chitosan and pectin based nanoparticles in the presence of sodium chloride. The 
absolute zeta potential values of both the chitosan and the pectin nanoparticles prepared 
under saline conditions were, however, predominately below 30 mV. As a rule of thumb, 
zeta potential values above an absolute value of 30 mV are considered necessary for good 
colloidal stability [99-101]. The stability of the particles towards changes in the size and 
compactness were therefore studied in paper III (chitosan) and IV (pectin) over a period of 
one month. 
The average Rh and the cNP values of the chitosan nanoparticles prepared in the presence of 
sodium chloride as a function of time are given in Figure 6.11 and Figure 6.12, respectively. 
Generally, only minor changes in the Rh or the cNP (less than 10%) were observed. 
 
Figure 6.11 – The average Rh of chitosan nanoparticles prepared in the presence of sodium chloride at 
0.05% chitosan (left) and 0.10% chitosan (right) as a function of time. Connection lines between the 
symbols are given in order to guide the eyes. Samples in which particle sedimentation was observed are 
omitted from the figure. 
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The chitosan nanoparticles that were found to be unstable over time, reflected as a change in 
the Rh or cNP, or by particle sedimentation, were prepared at 1) a high TPP to chitosan ratio, 
2) a high chitosan concentration and/or 3) a high sodium chloride concentration. 
Accordingly, the decreased zeta potentials found at high TPP to chitosan ratios (see Figure 
6.8), increased the possibility of particle aggregation over time. Moreover, the initial higher 
cNP values (Figure 6.10) and larger sizes (Figure 6.6) of the unstable combinations promoted 
particle sedimentation and instability. The self-associated AM-pectin nanoparticles prepared 
at a pectin concentration of 0.07% in the presence of 0.05 M NaCl were also found to be 
stable over a one month period. However, the AM-pectin nanoparticles crosslinked with 
ZnCl2 were only found to be stable after one week of storage: after one month aggregated 
flakes/flocs were observed in the samples. This increased aggregation tendency is most 
likely linked to the lower absolute zeta potential values found for these particles, if 
compared to both the self-associated AM-pectin nanoparticles and the chitosan 
nanoparticles (Figure 6.9 and Figure 6.8, respectively). 
 
Figure 6.12 – The local polymer concentration inside chitosan nanoparticles prepared in the presence of 
sodium chloride at 0.05% chitosan (left) and 0.10% chitosan (right) as a function of time. Connection 
lines between the symbols are given in order to guide the eyes. Samples in which particle sedimentation 
was observed are omitted from the figure. 
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As can be seen in Figure 6.11 and Figure 6.12, the unstable chitosan particles increased in 
size and compactness over time, except for one of the combinations that was found to be 
larger, but less compact after one week of storage. This combination was prepared at the 
most “extreme” conditions, and also exhibited the highest initial cNP value. Since 
aggregation and coalescence of nanoparticles is suppressed at sufficiently high cNP [109, 
110], it was proposed that the aggregates formed for this combination consisted of “hard 
spheres” packed together with open voids in-between the particles (paper III), which would 
explain the observed increase in size and decrease in particle compactness. This kind of 
aggregate structure was recently observed for chitosan-TPP-nanoparticles in a study of 
Huang and Lapitsky[111], and has also been proposed for other polymer systems [112].  
6.4 Interactionwithmucin
In order to evaluate the nanoparticles’ potential mucoadhesive properties, the in vitro 
interaction of mucin with two selected combinations of nanoparticles was studied. The 
nanoparticles were prepared in 0.05 M NaCl, at a polysaccharide concentration of 0.05% 
and a crosslinker to polysaccharide ratio of 15:85. In Figure 6.13, it can be observed that the 
vial containing chitosan nanoparticles mixed with mucin (vial marked with C+M), was quite 
turbid if compared to the vials containing chitosan nanoparticles (vial C) and mucin solution 
(vial M). Large flocs/aggregates could be seen by the naked eye, and these structures started 
to settle if left standing. In contrast, the mixture of AM-pectin nanoparticles with mucin 
(vial P+M) was not significantly more turbid than the controls (vial M and P) if controlled 
by the naked eye. 
 
Figure 6.13 – Vials containing (C) chitosan nanoparticles, (C+M) chitosan nanoparticles mixed with 
mucin, (M) mucin solution, (P+M) AM-pectin nanoparticles mixed with mucin, and (P) AM-pectin 
nanoparticles. The samples were homogeneous without any sign of phase separation (except for sample 
C+M, in which particle sedimentation was observed after some minutes if left standing); the apparent 
turbidity increase at the bottom of the samples is merely a photographic artefact. 
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In Table 6.1, the average Rh, PDI, zeta potential and transmittance values of the AM-pectin 
samples are displayed, along with the pH of the sample. No significant difference in the Rh 
of the AM-pectin nanoparticles and the mixture of AM-pectin nanoparticles and mucin can 
be observed. Furthermore, only a slight decrease in the transmittance was found. 
Consequently, the AM-pectin nanoparticles’ potential to interact with mucin appears rather 
low from these experiments. However, Klemetsrud et al. [98] have previously shown, by 
applying a similar method, that liposomes coated with AM-pectin interact with mucin. In 
these studies, the concentration of mucin solution was higher and the pectin was not 
crosslinked at the liposome surface, thus increasing the possibility for polymer chain 
entanglement. This may explain the different results obtained, since polymer entanglement 
has been indicated as an important interaction mechanism between pectin and mucin [113-
115]. Accordingly, pectin gel beads with increasing degrees of crosslinking, and thus less 
flexible and mobile chains, have been shown to be less mucoadhesive [91]. Chitosan, on the 
other hand, interacts strongly with mucin by electrostatic interactions [116], explaining the 
observed differences between the two types of polysaccharide based nanoparticles.  
 
Table 6.1 – Overview of the sample characteristics obtained in the in vitro interaction studies between 
crosslinked AM-pectin nanoparticles and mucin (n=3). 
Vial Rh
(nm)
PDI Transmittance
(%)
Zetapotential
(mV)
pH
(M) ʹͷͺάͳͲ ͲǤ͸ʹάͲǤͲʹ ͻͻǤʹ ǦͳͻǤͷάͳǤ͵ ͸Ǥ͸
Ǧ(P) ͵Ͳ͸άͳͶ ͲǤ͵ʹάͲǤͲͶ ͻͺǤͲ ǦʹͳǤͳάͳǤʹ ͶǤͲ
ǦΪ
(P+M) ͵Ͳͳάͳͳ ͲǤ͵ͷάͲǤͲͷ ͻ͸Ǥͷ ǦͳͻǤ͸άͲǤͺ ͶǤͳ
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7 Concludingremarks
The size, charge and compactness are important physicochemical properties of 
nanoparticulate drug delivery systems, linked to both mucus interaction and penetration [24, 
25], systemic distribution [10, 29] and drug release rates [33-35]. The particle compactness 
is, however, seldom reported in studies on polysaccharide and polymer based nanoparticles, 
probably due to experimental difficulties in estimating this parameter [117]. The particles 
prepared in this work were characterized with respect to particle size and charge by well-
known methods, while a theoretical method was developed in order to estimate the particle 
compactness (paper I). This method combines data from DLS and turbidity measurements to 
calculate the local polymer concentration inside the nanoparticles (cNP), as a measure of the 
particle compactness. The method is developed for spherical, monodisperse particles, and 
the total polymer concentration that exists in the form of nanoparticles must be known. 
These considerations could be assumed for both the crosslinked chitosan and pectin 
nanoparticles prepared in the presence of sodium chloride. This theoretically deduced 
method has also been adapted indirectly [98, 118] or directly [119] in other papers to 
discuss the compactness of polysaccharide or polymer based nanoparticulate systems. 
The results obtained in this thesis demonstrate that nanoparticles based on the 
polysaccharides chitosan and pectin could be prepared by ionotropic gelation with 
multivalent ions in the presence of sodium chloride. In pure water, however, chitosan 
microparticles or a macroscopic pectin network was formed instead of the desired 
nanoparticles. It was also found that non-crosslinked, self-associated pectin nanoparticles 
could be prepared in the absence of divalent cations (i.e., in the presence of sodium chloride 
only). All these observations can be explained by a change in the polysaccharide chain 
conformation and association in the presence of monovalent salt. Consequently, it can be 
concluded the solvent salinity is an important parameter to address in the preparation of 
nanoparticulate DDSs based on chitosan and pectin.  
It was also found that the nanoparticles’ physicochemical properties could be easily adjusted 
by varying the solvent salinity, the type and concentration of polysaccharide, and the 
crosslinker to polysaccharide ratio. Specifically, by changing the sodium chloride 
concentration of the solvent used in the particle preparation from 0.05 to 0.15 M, the 
average particle size and compactness of the chitosan nanoparticles were raised. Increasing 
the TPP to chitosan ratio, however, only moderately affected the average particle size, but 
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lead to a significant increase in the particle compactness. The chitosan concentration did not 
affect the particle compactness at low to moderate TPP to chitosan ratios, but significantly 
affected the particle size. This latter observation points out the possibility of preparing 
chitosan nanoparticles of different particle sizes, but of equal particle compactness by 
simply adjusting the chitosan concentration. Interestingly, increasing the AM-pectin 
concentrations resulted in a size increase of the self-associated nanoparticles, but not of the 
crosslinked nanoparticles. This lack in size increase of the crosslinked AM-pectin 
nanoparticles was concurrent with an increase in the particle compactness and explained by 
a sensitive relationship between intra- and inter-particle crosslinking. The main difference 
between the chitosan and the pectin nanoparticles prepared was that they exhibited positive 
and negative zeta potentials, respectively. Moreover, the chitosan nanoparticles were 
generally smaller and more compact than the pectin nanoparticles.  
Despite the reduced absolute zeta potential values of the nanoparticles prepared in the 
presence of sodium chloride, the chitosan and the pectin nanoparticles were mainly found to 
be colloidally stable after one week of storage. Several of the nanoparticle suspensions 
could also be stored for an entire month without significant changes in the average particle 
size, charge and compactness. The fact that the nanoparticles are stable in suspension for 
several days may facilitate simple screening studies because the extra preparation step of 
freeze-drying can be avoided. 
The positively charged chitosan nanoparticles interacted strongly with the negatively 
charged mucin in vitro. This indicates that the chitosan nanoparticles are likely to be 
immobilized in the more rapidly cleared upper part of the mucus layer [25], despite being 
relatively small. In contrast, the negatively charged pectin nanoparticles showed little 
interaction with mucin in vitro, and may thus possibly penetrate deeper in the mucus mesh, 
given that the pore size at the mucosal site is sufficiently large. 
The results obtained in this thesis can be used as a guide in future studies on nanoparticles 
based on chitosan and pectin, and possibly other polysaccharides with polyelectrolyte 
properties, such as alginate and hyaluronic acid. 
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8 Futureperspectives
The underlying basis of this work was that nanoparticles based on mucoadhesive 
polysaccharides can possibly improve drug treatment locally or enhance the systemic 
delivery of drugs after administration to mucosal routes. There are several mucosal 
administration routes with a need for improvement in local therapy, or where the 
administration of drugs for systemic effects would be appropriate [7, 8, 24, 25, 40, 120-
124]. The nasal route is one good example studied for local delivery of vaccines, and for 
direct nose-to-brain delivery through the olfactory region [123].  
The findings in this thesis offer a decent platform for further studies on the applicability of 
polysaccharide based nanoparticles for drug delivery purposes. However, several future 
studies should be performed to obtain an improved understanding of polysaccharide based 
nanoparticles as a DDS. One of the major findings in this study was that the ionic strength 
had a tremendous effect on the particle preparation and particle characteristics, which could 
mainly be explained by a change in polysaccharide chain conformation. The influence of 
this conformational change on the encapsulation efficiency of drugs into the particles was 
out of the scope of this thesis; however, it is tempting to assume that the drug encapsulation 
process will be affected as well. It would thus be interesting to look into the possible 
impacts of the ionic strength and the particle compactness on the encapsulation and release 
rates of drugs with various charge and molecular weights. 
Moreover, studies investigating the fate of the nanoparticles in the human body post 
mucosal administration can highly contribute to the evaluation of their suitability as DDSs 
for local or systemic delivery. As a first step, the mucoadhesive properties of the 
nanoparticles could be evaluated further in vitro or ex vivo in the presence of a suitable 
isotonic buffer or simulated body fluid. This would be especially interesting for the AM-
pectin nanoparticles that showed few signs of interaction with mucin under the present 
experimental conditions. Evaluation of the particles’ toxicity profile in vitro using suitable 
mucosal cell lines should also be performed, before the fate and action of the DDSs were to 
be evaluated for a specific application in vivo.  
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Optical-scattering method for the determination of the local polymer concentration
inside nanoparticles
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We have developed a method based on the Mie theory for determining the local polymer concentration inside
spherical nanoparticles, thereby obtaining vital information about whether the particles are swelling in the solvent
or if they are contracted into a more compact structure. In addition, this method can be used to calculate the
number density of the particles, the molecular weight of the particles, and (if Mn of the polymer is known) the
aggregation number. The calculations are based on the relationship between the size of the nanoparticles and
the turbidity of the sample.
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Polymer nanoparticles have been the subject of a vast
number of studies, both to gain a better fundamental un-
derstanding of their properties [1] and to develop numerous
interesting applications for them [2]. Polymer nanoparticles
can be made either by covalently cross-linking polymers into
permanent particles, sometimes referred to as nanogels, or
by assembling several polymer units together by physical
interactions such as hydrogen bonds, electrostatic forces,
or hydrophobic associations. The size of the particles is
dependent on the amount of polymer they contain and on how
much they swell in the solvent they are suspended in. However,
the attractive forces that cause the particles to contract will
often induce aggregation between the nanoparticles. The
competition between intra- and interparticle associations is
often observed for stimuli-responsive systems [1,3–7] where
the attractive forces between the polymer chains can be
turned on and off by changes in external parameters such
as temperature, solvent salinity, or pH. This can make it
difﬁcult to interpret changes in particle size, since an increase
in size can be caused by either swelling or aggregation,
and constant size can actually be the result of a cancelation
between contraction and aggregation of the particles [6].
In order to gain a proper understanding of nanoparticu-
lar systems, it is important to characterize the degree of
swelling (i.e., the local polymer concentration inside the
nanoparticles).
In addition to being helpful in the interpretation of changes
in particle size, the local polymer concentration inside the
nanoparticles is in itself important for various applications.
Polymer nanoparticles are of interest for controlled drug
delivery [8], and one of the factors that affect the release
rate of drugs from nanoparticle suspensions is the degree
of swelling of the particles, as the more open structure of
swollen nanoparticles has been observed to increase the drug
release rate from the particles [9–11]. Polymer nanoparticles
also can be used to make temperature-responsive polymeric
photosensitizers, which have been found to be dependent on
the hydration and dehydration of the nanoparticles [12,13],
*a.l.kjoniksen@kjemi.uio.no
that is, the local polymer concentration inside the nanoparti-
cles. Another application of polymer nanoparticles is water
puriﬁcation, and in connection with this it has been suggested
that the degree of particle swelling can control the uptake and
release of Pb(II) ions [14].
The aggregation of polymer nanoparticles into larger
aggregates is also governed by the local polymer concentration
inside the nanoparticles [1,15–17]. Aggregate formation is
dependent on the contact time between the particles when
they collide (τc) and the time needed to establish a permanent
chain entanglement between two approaching particles (τe).
When τc  τe, aggregate formation is suppressed since
the colliding particles do not have time to stick together,
and the particles behave as elastic bodies on the collision
time scale. Tanaka [15,16] showed that τc and τe can be
estimated by
r0
〈υ〉 < τc <
r20
D
and τe ∼ a
2
mN
3
mφ
3/2
NP
Dm
(1)
where r0 is the interaction range between the particles, 〈υ〉 is
the thermal velocity magnitude (〈υ〉 ∼ (kT /mp)1/2, where k
is Boltzmann’s constant, T is the absolute temperature, mp is
the mass of the particle), D is the diffusion coefﬁcient of the
particles (D = kT6πη0R , where η0 is the viscosity of the solvent
and R is the radius of the particle), am is the length of a unit
monomer, Nm is the number of monomers, ϕNP is the volume
fraction of polymer inside the particles, andDm is the diffusion
coefﬁcient of the monomer. Accordingly, τ e increases with the
aggregation number and with the volume fraction of polymer
inside the particles, and aggregation is therefore suppressed
when the local polymer concentration inside the nanoparticles
is high enough.
The degree of swelling of nanoparticles has been deter-
mined by separating the nanoparticles from the solvent by
ﬁltration and comparing the weight of the swollen nanopar-
ticles with their dry mass [9]. However, separation of small
nanoparticles from the solvent can be experimentally difﬁcult,
and this method is not very well suited for nanoparticles that
are sensitive to changes in temperature or concentration. The
local polymer concentration inside nanoparticles can also be
determined by comparing their size with the molecular weight
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of the particles [1]. Unfortunately, determining the molecular
weight of nanoparticles can be experimentally challenging.
The aggregation number of the particles is often concentration
dependent, which excludes the use of separation methods
which will dilute the system system (such as gel permeation
chromatography, size exclusion chromatography or asymmet-
ric ﬂow ﬁeld-ﬂow fractionation), and even the determination
of the molecular weight by a traditional Zimm plot, for
which a concentration series is needed. For very low polymer
concentrations, the molecular weight can be estimated from
a single polymer concentration from either a Zimm plot for
small particles or a Guinier plot for large particles [1], but the
limitation to very low concentrations restricts the usefulness of
these techniques. A method for determining the local polymer
concentration inside nanoparticles from experiments that can
easily be conducted on nanoparticle suspensions at various
temperatures and polymer concentrations is therefore needed.
In this paper, we illustrate how the local polymer concentration
inside spherical nanoparticles, as well as their number density,
molecular weight, and aggregation number, can be determined
from the size of the nanoparticles and the turbidity of the
nanoparticle suspension.
The turbidity (τ ) of a sample containing nanoparticles can
be expressed by Lambert-Beer’s law:
τ = − 1
L
ln
(
I
I0
)
, (2)
where L is the thickness of the cell, I is the light transmitted
through the sample, and I0 is the light transmitted through
the solvent. The turbidity of the sample is dependent on the
number density of particles N (number of particles per unit
volume), the radius R of the particles, and the difference in
refractive index between the particles and the surrounding
media [18]:
τ = NπR2Qext, (3)
where Qext is the Mie extinction efﬁciency. For spherical
particles that do not absorb light at the considered wave-
length (λ), the Mie extinction efﬁciency can be expressed
as [19,20]
Qext = 2
[
1 − 2
ρ
(
sin ρ − 1
ρ
(1 − cos ρ)
)]
, (4)
where ρ = 4πR(m−1)
λ
, and m = nNP
n0
is the ratio between the
refractive index of the particle (nNP) and the refractive index
of the solvent (n0). The refractive index of the particle can
be expressed in terms of the refractive index increment of
the polymer (dn/dc) by nNP = n0 + (dn/dc ) cNP, where cNP
is the local polymer concentration inside a nanoparticle. This
gives us
ρ = 4π R (dn/dc) cNP
λn0
= wcNP, (5)
where w = 4πR(dn/dc)
λn0
.
For a sample with a total volume Vt , the total mass
of polymer in the nanoparticles can be expressed as mt =
NNPmNP, where mNP is the mass of polymer in a single
nanoparticle andNNP = NVt is the total number of particles in
the sample. The total polymer concentration can be expressed
as ct = mtVt , and the local polymer concentration inside a single
nanoparticle with a volume VNP is
cNP = mNP
VNP
= 3mNP
4π R3
. (6)
Accordingly, the number density of particles can be
expressed as
N = 3ct
4cNPπ R3
. (7)
By combining Eqs. (3), (4), (5), and (7), we can now express
the turbidity as
τ = 3ct
2cNPR
(
1 − 2
wcNP
{
sin(wcNP)
− 1
wcNP
[1 − cos(wcNP)]
})
. (8)
As can be seen from Eq. (8), the turbidity is now expressed
as a function of cNP. For a sample containing spherical
nanoparticles with a relatively narrow size distribution, we
can now determine the local polymer concentration inside the
nanoparticles.
Chitosan is a nontoxic biopolymer with promising prop-
erties for various drug delivery purposes [21]. It can be
crosslinked by tripolyphosphate (TPP), which is a polyanion
that interacts electrostatically with the positively charged
chitosan [21]. By adding TPP to dilute solutions of chitosan,
we can thereby form physically cross-linked nanoparticles.We
have measured the hydrodynamic radius of chitosan (Protasan;
chitosan chloride) nanoparticles cross-linked by TPP in the
presence of 0.1MNaCl at different cross-linker concentrations
by dynamic light scattering (DLS). The hydrodynamic radius
of the nanoparticles is determined from DLS measurements
as described previously [5]. As can be seen from Fig. 1, when
the cross-linker concentration is increased, the radius goes
through a slight maximum before it decreases markedly at
high cross-linking densities.
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FIG. 1. Hydrodynamic radius of chitosan nanoparticles deter-
mined by DLS as a function of cross-linker concentration. The errors
are of approximately the same size as the symbols, and the line is
only a guide for the eye.
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FIG. 2. (Color online) The turbidity of suspensions of chitosan
nanoparticles at the indicated cross-linker concentrations as a function
of the local polymer concentration inside the nanoparticles calculated
fromEq. (8) using the sizes determined byDLS are represented by the
sloping (blue) lines. The horizontal (red) lines indicate the turbidities
determined from the transmittance data from Eq. (2).
Considering both the relatively high cross-linker concen-
trations used and that the presence of NaCl in the sample
will promote aggregation, it is reasonable to assume that
practically all chitosan is in the form of nanoparticles and very
little polymer is left as free polymer chains in the solution.
This assumption is corroborated by the measured correlation
functions, which exhibit only one relaxation mode with a
narrow size distribution. We therefore can assume that the
total polymer concentration in the sample is in the form of
nanoparticles, giving us ct = 1.0 mg/ml, which equals the
total chitosan concentration in the samples. We have measured
the refractive index increment of chitosan in 0.1 M NaCl to be
dn/dc = 0.157 g/ml, and the refractive index of the solvent is
n0 = 1.3337. The transmittance of the samples was measured
on a spectrophotometer at a wavelength of 633 nm, and the
turbidity was calculated from Eq. (2).
In Fig. 2, the turbidity of each sample is plotted as a function
of cNP from Eq. (8), using the hydrodynamic radii measured
by DLS. The horizontal lines indicate the turbidities calculated
from Eq. (2). The local polymer concentration inside the
nanoparticles can be determined from the intercept between
the two lines. Figure 3(a) illustrates how cNP varies with the
cross-linker density, and as expected a higher cross-linker
concentration increases the local polymer concentration inside
the particles as enhanced intraparticle cross links causes the
particles to contract.
Having determined cNP, we can now calculate the number
density of the particles by using Eq. (7). From Fig. 3(b) we
can see that the number density decreases with increasing
cross-linker concentration, indicating that the cross-linking
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FIG. 3. (a) The local polymer concentration in the chitosan
nanoparticles, (b) the number density of nanoparticles, (c) the
molecularweight of the nanoparticles, and (d) the aggregation number
of chitosan in the nanoparticles as a function of the cross-linker
concentration. The lines are only guides for the eye.
process is not only establishing intraparticle cross links within
pre-existing polymer aggregates, but in addition interparticle
cross links are binding several aggregates together, thereby
reducing the total number of particles in the sample. From
Eq. (6), we can see that mNP = 43π R3cNP, which gives us the
molecular weight of the particles as
MNP = 43π R3cNPNA, (9)
where NA is Avogadro’s number. We can now determine the
aggregation number from
Nagg = MNP
Mn
, (10)
where Mn is the number average molecular weight of the
polymer (1.2 × 105). As can be seen from Figs. 3(c) and
3(d), both the molecular weight of the particles and the
aggregation number increase as more cross linker is added
to the sample, again illustrating that higher cross-linking
densities enhances interparticle aggregation. Comparing the
various characteristics of the particles, we can see that at low
cross-linker concentrations, the contraction of the particles is
relatively modest [Fig. 3(a)] while the aggregation number
rises markedly [Fig. 3(d)]. This causes the observed increase
in size (Fig. 1). At high cross-linker concentrations, the aggre-
gation number of the nanoparticles is nearly constant, while
the local concentration inside the particles rises markedly. At
this stage both Nagg and cNP are high, and we can assume
that τc  τe. Further aggregation is therefore suppressed,
and the cross-linking process is mainly taking place inside
the existing particles, causing them to contract into smaller
particles (Fig. 1).
In summary, we have developed a method for determining
the local polymer concentration inside polymer nanoparti-
cles. The method has been tested on chitosan nanoparticles
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crosslinked by TPP and shows that as expected cNP increases
with the cross-linking density. We have also been able to
determine the number density of particles in the solution, the
molecular weight of the particles, and the aggregation number
of chitosan in the nanoparticles. The obtained results are in
agreement with what one would expect for the considered
nanoparticles.
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